Aura Biosciences, Inc.
AURA · XNASCIK 1501796fmd_1QPW2NQQV7SXSAJ0NEBW2N0RHJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Realized investment gains (losses) | – | – | (0) | – | – | – |
| Net interest income after provision | (0) | 0 | 2 | 9 | 9 | 7 |
| Research and development | 18 | 25 | 42 | 65 | 73 | 90 |
| Operating income | (22) | (35) | (60) | (85) | (96) | (113) |
| Other non-operating income (expense) | – | (0) | 2 | 9 | 9 | 7 |
| Income before taxes | – | – | (59) | (76) | (87) | (106) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (59) | (76) | (87) | (106) |
| Net income | (22) | (35) | (59) | (76) | (87) | (106) |